A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor. There is interest in evaluating alternate dosing schedules and novel combinations of pano for the treatment of upper aerodigestive and lung malignancies; thus we evaluated it in combination with Taxol, a chemotherapeutic with acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Samaraweera, Leleesha, Adomako, Alfred, Rodriguez-Gabin, Alicia, McDaid, Hayley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432488/
https://www.ncbi.nlm.nih.gov/pubmed/28507307
http://dx.doi.org/10.1038/s41598-017-01964-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432488/
https://www.ncbi.nlm.nih.gov/pubmed/28507307
http://dx.doi.org/10.1038/s41598-017-01964-1

Ejemplares similares